Dr. Timothy Miller’s research focuses on bringing novel therapeutic strategies to neurodegenerative diseases. As we work toward the goal of bringing these new therapies to human clinical trial, our exciting research often attracts national and international attention.
Hosts: Jinsy A. Andrews, MD, MSc, Columbia University Medical Center and Timothy M. Miller, MD, PhD, Washington University (NEALS Co-Chairs) Panelists: Richard Bedlack, MD, PhD, Duke ALS Clinic; Merit Cudkowicz, MD, Sean M. Healey & AMG Center for ALS at Mass General Hospital; Pamela Kittrell, MSN, RN, CCRC, UT Health San Antonio; Jeffrey D. Rothstein, […]
Hosts: Jinsy A. Andrews, MD, MSc, Columbia University Medical Center and Timothy M. Miller, MD, PhD, Washington University (NEALS Co-Chairs) Panelists: Richard Bedlack, MD, PhD, Duke ALS Clinic; James D. Berry, MD, MPH, Sean M. Healey & AMG Center for ALS at Mass General Hospital; Merit Cudkowicz, MD, Sean M. Healey & AMG Center for ALS […]
Presenter: Timothy Miller, MD, PhD, Washington University in St. Louis This webinar provides introductory-level instruction on how to search for ALS clinical trials. You will learn what resources to use to find open ALS clinical trials and where to look for specific information such as eligibility criteria, trial site locations, and if traveling is required. […]
Presenter: Timothy Miller, MD, PhD, Washington University in St. Louis Novel gene-targeted therapies are being developed for ALS and other neurodegenerative diseases. We will discuss how these drugs work and some of the research driving these clinical trials.
The Sean M. Healey & AMG Center for ALS at Mass General has received approval from the U.S. Food and Drug Administration (FDA) to proceed with administering three proposed drug regimens in the HEALEY ALS Platform Trial – the first trial of its kind for amyotrophic lateral sclerosis (ALS).
Recognized for developing experimental treatment for ALS Timothy Miller, MD, PhD, the David Clayson Professor of Neurology at Washington University School of Medicine in St. Louis, and a group of his colleagues have received the inaugural Healey Center International Prize for innovation in amyotrophic lateral sclerosis (ALS) research from the Sean M. Healey & AMG […]
Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers Our team’s hard work has been published in Neurology. This paper profiles the clinical features, such as age at disease onset, survival duration, and measures of disease progression, of ALS patients with mutations in the C9orf72 gene. By defining the natural history of this […]
The award goes to Timothy Miller, MD, PhD, of Washington University School of Medicine in St. Louis, Don Cleveland, PhD, of the Ludwig Institute at the University of California at San Diego, Richard Smith, MD, of the Center of Neurological Study in La Jolla, California, Toby Ferguson, MD, PhD, for Biogen and Frank Bennett, PhD, […]
Biomarkers are measures reflective of biological processes that occur in the body. In the setting of disease, biomarkers may be used for diagnostic, prognostic or treatment monitoring purposes.
With funds raised through the ALS Ice Bucket Challenge, The ALS Association has been able to invest significantly in the identification of biological indicators (or biomarkers) for ALS.
A genetic therapy that increases or lowers levels of a protein raises hopes for a treatment for neurological disorders.
An early stage trial of an investigational therapy for amyotrophic lateral sclerosis (ALS) suggests that people could tolerate the experimental drug and, in exploratory results, the experimental drug was linked to possible slower progression in people with a genetic form of the disease caused by mutations in a gene called superoxide dismutase 1 (SOD1).